Printer Friendly

Tuberculosis: Guidelines Changed for Latent TB Treatment.

The U.S. Centers for Disease Control and the American Thoracic Society have issued new guidelines calling for more caution in using the two-month regimen of rifampin and pyrazinamide. The change resulted from reports of 21 cases of severe liver injury with the two-drug regimen. Five of these patients died, and 16 recovered.

The new guidelines were published in the August 31, 2001 MMWR (Morbidity and Mortality Weekly Report), volume 50, number 34, pages 733-735. We cannot summarize them because there are many special cases. For most patients, especially those who are HIV-negative, the older nine-month regimen of isoniazid (INH) should be used. The persons with HIV, the guidelines include the following:

"Available data do not suggest excessive risk for severe hepatitis associated with RIF-PZA treatment among HIV-infected persons. In a large multinational trial, HIV-infected patients treated with RIF-PZA had lower rates of serum aminotransferarase (AT) elevations than those given INH alone. The RIF-PZA regimen also was well tolerated when given twice weekly to HIV-infected persons in Zambia and Haiti. However, experience from trials may not translate to all clinical practice settings, and it may be prudent to use 9 months of daily INH for treatment of HIV-infected persons with LBTI [latent TB infection] when completion of treatment can be assured."
COPYRIGHT 2001 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Article Type:Brief Article
Geographic Code:1USA
Date:Sep 21, 2001
Previous Article:September 11: What Happens Now?
Next Article:Malawi Plan to Control AIDS Epidemic: Interview with David Scondras, Search for a Cure.

Related Articles
Tuberculosis-related deaths within a well-functioning DOTS control program. (Research).
Multidrug-resistant tuberculosis in Central Asia.
Pharmacy data for tuberculosis surveillance and assessment of patient management.
Anti-TB spending abroad could save money overall.
Multidrug-resistant tuberculosis in military recruits.
Nosocomial tuberculosis in India.
Multidrug-resistant tuberculosis management in resource-limited settings.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters